Why Are First Wave BioPharma Shares Tanking Today
Portfolio Pulse from Vandana Singh
First Wave BioPharma Inc's shares are trading lower after the company received topline results from its Phase 2 SPAN trial for the treatment of exocrine pancreatic insufficiency in cystic fibrosis patients. The preliminary data indicates that the primary efficacy endpoint was likely not achieved. The company plans to pursue an End-of-Phase 2 meeting with the FDA in the fourth quarter of 2023.
July 13, 2023 | 1:36 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
First Wave BioPharma's stock price is falling due to disappointing preliminary results from its Phase 2 SPAN trial.
The company's stock price is directly impacted by the results of its clinical trials. The preliminary data from the Phase 2 SPAN trial indicates that the primary efficacy endpoint was likely not achieved, which is a negative outcome. This has led to a decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100